Drug intelligence / Profile preview

Mansoura Univ. VEGFR-2 compound 10c

Development stage: Preclinical
Lead developer: Mansoura University

Overview

Mansoura Univ. VEGFR-2 compound 10c: sourced facts only. name: "Results proved that compound 10c exhibited outstanding VEGFR-2 inhibition (IC50 = 0.104 μM) compared to sunitinib." [PMID:39850549]; target: "Results proved that compound 10c exhibited outstanding VEGFR-2 inhibition (IC50 = 0.104 μM) compared to sunitinib." [PMID:39850549]; developer: "Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt [email protected] [email protected] [email protected]." [PMID:39850549]; stage: "Furthermore, compound 10c showed a significant reduction in tumor volume in Swiss albino female mice as an in vivo breast cancer model." [PMID:39850549]

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on Mansoura Univ. VEGFR-2 compound 10c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mansoura Univ. VEGFR-2 compound 10c.